Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1604 plus bevacizumab vs sorafenib in first-line advanced hepatocellular carcinoma
CTR20200924Phase 3Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab in hepatocellular carcinoma (HCC), sponsored by Qilu Pharmaceutical. Started May 2020; status: active.
02
Drugs
iparomlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20200924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200924.